Aktienanalyse zu Ardelyx, Inc. (ARDX)ARDXArdelyx, Inc.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ardelyx Inc is not a good buy right now due to its current price of $3.09 being significantly below its 200-day simple moving average of $5.508. Additionally, the stock has a low RSI of 30.437, indicating it is oversold, but this is coupled with a troubling 49.76% year-to-date decline, suggesting ongoing weakness. The recent legal setbacks regarding Medicare reimbursement for its drug Xphozah and a class action lawsuit add further risk, making it a poor investment choice at this time.

7 analysts cover ARDX: 7 rate it Buy, 0 Hold and 0 Sell. The average price target is 14.86.